Aclarion (ACON) Registration Filing summary

Company overview and business model

• Healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments for low back and neck pain, targeting a $134.5B U.S. market.

• Employs AI for quality control and aspires to use AI/machine learning for deeper analysis and clinical outcome prediction.

• Initial focus is on improving surgical outcomes for lumbar spine pain, with plans to expand to conservative therapies and other pain populations.

• Holds a portfolio of 22 U.S. patents, 17 foreign patents, and several pending applications, with key technology licensed from UCSF.

• Clinical studies show improved surgical outcomes when technology is used to identify pain-generating discs.

Financial performance and metrics

• Last reported sale price of common stock on September 18, 2024, was $0.1760 per share; aggregate market value of outstanding common stock held by non-affiliates is $3,268.45.

• Stockholders' equity as of June 30, 2024, was $1,642,177.

• Auditors have included explanatory paragraphs about the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds intended for market development, clinical evidence, product development and quality, general and administrative support, debt retirement, and other general corporate purposes.